Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis

被引:4
作者
Juanola, Oriol [1 ]
Frances, Ruben [2 ,3 ,4 ,5 ]
Caparros, Esther [2 ,3 ]
机构
[1] Ente Osped Cantonale, Labs Translat Res, Bellinzona, Switzerland
[2] Univ Miguel Hernandez, Dept Med Clin, Hepat & Intestinal Immunobiol Grp, Alicante, Spain
[3] Hosp Gen Univ Dr Balmis, IIS ISABIAL, Alicante, Spain
[4] Univ Miguel Hernandez, Inst IDIBE, Elche, Spain
[5] Inst Salud Carlos III, CIBERehd, Madrid, Spain
关键词
Liver disease; Gut-liver axis; Bacterial translocation; Dysbiosis; Cirrhosis; ANTIBIOTIC-PROPHYLAXIS; CLINICAL-TRIAL; BILE-ACIDS; CIRRHOSIS; BARRIER; PLACEBO; INFLAMMATION; OVERGROWTH; RIFAXIMIN; EFFICACY;
D O I
10.1159/000535962
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The global burden of liver disease and cirrhosis has been progressively increasing in the last decade. The interplay between gut microbiota and immune system and the bidirectional relationship with the liver, known as the gut-liver axis, has arisen as a fundamental aspect of liver disease. Summary: Alterations of the gut microbiome have been described and include both dysbiotic microbial signatures and intestinal bacterial overgrowth. The integrity of the intestinal epithelial barrier is essential for preventing the access of harmful substances and bacterial products into the host. Bacterial translocation due to altered host-microbiota interactions triggers local immune cell activation and facilitates a chronic inflammatory state that can ultimately lead to immune exhaustion, characteristic of cirrhosis. In cirrhosis, breakdown of the gut vascular barrier allows access of bacterial products to portal blood circulation and facilitates their influx into the liver, further contributing to disease progression. Key Messages: A better understanding of the contributing factors to pathological bacterial translocation and the impact of dysbiosis in liver disease will lead to achieve innovative therapeutic strategies in cirrhosis.
引用
收藏
页码:12 / 19
页数:7
相关论文
共 63 条
[1]   Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on-chronic liver failure [J].
Agarwal, Banwari ;
Canizares, Rafael Banares ;
Saliba, Faouzi ;
Ballester, Maria Pilar ;
Tomescu, Dana Rodica ;
Martin, Daniel ;
Stadlbauer, Vanessa ;
Wright, Gavin ;
Sheikh, Mohammed ;
Morgan, Carrie ;
Alzola, Carlos ;
Lavin, Phillip ;
Green, Daniel ;
Kumar, Rahul ;
Sacleux, Sophie Caroline ;
Schilcher, Gernot ;
Koball, Sebastian ;
Tudor, Andrada ;
Minten, Jaak ;
Domenech, Gema ;
Aragones, Juan Jose ;
Oettl, Karl ;
Paar, Margret ;
Waterstradt, Katja ;
Bode-Boger, Stefanie M. ;
Ibanez-Samaniego, Luis ;
Gander, Amir ;
Ramos, Carolina ;
Chivu, Alexandru ;
Stange, Jan ;
Lamprecht, Georg ;
Sanchez, Moises ;
Mookerjee, Rajeshwar P. ;
Davenport, Andrew ;
Davies, Nathan ;
Pavesi, Marco ;
Andreola, Fausto ;
Albillos, Agustin ;
Cordingley, Jeremy ;
Schmidt, Hartmut ;
Carbonell-Asins, Juan Antonio ;
Arroyo, Vicente ;
Fernandez, Javier ;
Mitzner, Steffen ;
Jalan, Rajiv .
JOURNAL OF HEPATOLOGY, 2023, 79 (01) :79-92
[2]   Cirrhosis-associated immune dysfunction [J].
Albillos, Agustin ;
Martin-Mateos, Rosa ;
van der Merwe, Schalk ;
Wiest, Reiner ;
Jalan, Rajiv ;
Alvarez-Mon, Melchor .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (02) :112-134
[3]   The gut-liver axis in liver disease: Pathophysiological basis for therapy [J].
Albillos, Agustin ;
de Gottardi, Andrea ;
Rescigno, Maria .
JOURNAL OF HEPATOLOGY, 2020, 72 (03) :558-577
[4]   Immunomodulation by endothelial cells - partnering up with the immune system? [J].
Amersfoort, Jacob ;
Eelen, Guy ;
Carmeliet, Peter .
NATURE REVIEWS IMMUNOLOGY, 2022, 22 (09) :576-588
[5]   The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis [J].
Arroyo, Vicente ;
Angeli, Paolo ;
Moreau, Richard ;
Jalan, Rajiv ;
Claria, Joan ;
Trebicka, Jonel ;
Fernandez, Javier ;
Gustot, Thierry ;
Caraceni, Paolo ;
Bernardi, Mauro .
JOURNAL OF HEPATOLOGY, 2021, 74 (03) :670-685
[6]   Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial [J].
Bajaj, Jasmohan S. ;
Salzman, Nita H. ;
Acharya, Chathur ;
Sterling, Richard K. ;
White, Melanie B. ;
Gavis, Edith A. ;
Fagan, Andrew ;
Hayward, Michael ;
Holtz, Mary L. ;
Matherly, Scott ;
Lee, Hannah M. ;
Osman, Majdi ;
Siddiqui, Mohammad S. ;
Fuchs, Michael ;
Puri, Puneet ;
Sikaroodi, Masoumeh ;
Gillevet, Patrick M. .
HEPATOLOGY, 2019, 70 (05) :1690-1703
[7]   Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort [J].
Bajaj, Jasmohan S. ;
Idilman, Ramazan ;
Mabudian, Leila ;
Hood, Matthew ;
Fagan, Andrew ;
Turan, Dilara ;
White, Melanie B. ;
Karakaya, Fatih ;
Wang, Jessica ;
Atalay, Rengul ;
Hylemon, Phillip B. ;
Gavis, Edith A. ;
Brown, Robert ;
Thacker, Leroy R. ;
Acharya, Chathur ;
Heuman, Douglas M. ;
Sikaroodi, Masoumeh ;
Gillevet, Patrick M. .
HEPATOLOGY, 2018, 68 (01) :234-247
[8]   Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis [J].
Bevins, Charles L. ;
Salzman, Nita H. .
NATURE REVIEWS MICROBIOLOGY, 2011, 9 (05) :356-368
[9]   Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis [J].
Caparros, Esther ;
Juanola, Oriol ;
Gomez-Hurtado, Isabel ;
Puig-Kroger, Amaya ;
Pinero, Paula ;
Zapater, Pedro ;
Linares, Raquel ;
Tarin, Fabian ;
Martinez-Lopez, Sebastian ;
Gracia-Sancho, Jordi ;
Gonzalez-Navajas, Jose M. ;
Frances, Ruben .
CELLS, 2020, 9 (05)
[10]   The Use of Rifaximin in Patients With Cirrhosis [J].
Caraceni, Paolo ;
Vargas, Victor ;
Sola, Elsa ;
Alessandria, Carlo ;
de Wit, Koos ;
Trebicka, Jonel ;
Angeli, Paolo ;
Mookerjee, Rajeshwar P. ;
Durand, Francois ;
Pose, Elisa ;
Krag, Aleksander ;
Bajaj, Jasmohan S. ;
Beuers, Ulrich ;
Gines, Pere .
HEPATOLOGY, 2021, 74 (03) :1660-1673